cBAF Inhibitors for Improving T Cell Immunotherapy (SJ-22-0015)

St. Jude Reference #SJ-22-0015


Researchers at St Jude identified proteins that help decide T cell fate and used that finding to improve CAR-T cell therapy in a solid tumor model.  The improvement comprises  inhibition of Arid1a (a component of the BAF complex) to increase persistence  of CAR-T cells in patients, leading to a more durable response. This represents a generic improvement that can be used to increase the efficacy of any CAR-T cell therapy.

A Nature publication describing this finding that transient inhibition of Arid1a with RBD-K98645985 during CAR-T cell generation promote memory function and improve tumor control published June 22, 2022.


Treg modulation, regulatory T cells, factor Foxp3 gene, chromatin looping, enhances or dampens Treg cell function, natural potency, autoimmune diseases, metabolic dysregulation, tissue regeneration, age-related neurodegeneration, cancer, gene therapy, cell therapy.

Granted patents or published applications

Application filed, available under confidentiality

Related scientific references

Ao Guo, Hongling Huang, Zhexin Zhu, Mark J. Chen, Hao Shi, Sujing Yuan, Piyush Sharma, Jon P. Connelly, Swantje Liedmann, Yogesh Dhungana, Zhenrui Li, Dalia Haydar, Mao Yang, Helen Beere, Jason T. Yustein, Christopher DeRenzo, Shondra M. Pruett-Miller, Jeremy Chase Crawford, Giedre Krenciute, Charles W. M. Roberts, Hongbo Chi, Douglas R. Green. cBAF complex components and MYC cooperate early in CD8+ T cell fate. Nature, 2022; DOI: 10.1038/s41586-022-04849-0

Licensing opportunities

We are seeking partners to develop and use this invention for gene and cell therapies. Contact:

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.